Additive Obinutuzumab Achieves High Remission Rates in Rituximab-Refractory Membranous Nephropathy
Obinutuzumab may represent an attractive alternative therapy in rituximab-refractory patients. Larger prospective studies are needed to validate these findings. .
Authors
- Xinfang Xie (ORCID: https://orcid.org/0000-0002-0872-2986)
- Dan Niu (ORCID: https://orcid.org/0000-0002-0715-7946)
- Ahmed Khalaf (ORCID: https://orcid.org/0000-0002-0355-1516)
- Jing Li (ORCID: https://orcid.org/0000-0001-9392-6600)
- Xiaotian Zhang (ORCID: https://orcid.org/0000-0001-5267-7871)
- Guiqing Xu
- Huixian Li (ORCID: https://orcid.org/0000-0002-3713-8017)
- Wanhong Lu
- Jiping Sun (ORCID: https://orcid.org/0000-0003-3555-9341)
- Jie Feng (ORCID: https://orcid.org/0000-0001-6969-9356)
Institutions
- First Affiliated Hospital of Xi'an Jiaotong University (CN)
- Xi'an Jiaotong University (CN)
Publication Details
- Journal
- American Journal of Nephrology
- Published
- 2025-05-19
- DOI
- https://doi.org/10.1159/000545995
- Citations
- 2
- Primary Topic
- Renal Diseases and Glomerulopathies
- Type
- article
- Field-Weighted Citation Impact
- 2.86